A phase I/II study of THV02 in patients with adult T-cell Leukemia/Lymphoma.
Phase of Trial: Phase I/II
Latest Information Update: 12 Feb 2015
At a glance
- Drugs THV 02 (Primary)
- Indications Adult T-cell leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors THERAVECTYS
- 12 Feb 2015 New trial record
- 04 Feb 2015 According to Theravectys media release, European Medicines Agency (EMA) has granted Orphan Drug Designation to THV02 for the treatment of adult T-cell leukemia/lymphoma.
- 04 Feb 2015 According to Theravectys media release, recruitment is planned to begin at the end of Q3 2015 in Europe and further proceed to the U.S and Japan in 2016.